• Featured Story

    20141013-biotech-etf

    There are more than 1,000 biotech companies in North America alone. They cover a wide range of sectors including pharmaceuticals, biologics, generics, and medical devices.

    But finding the right stocks in such a broad industry is no easy task.

    That's why we've targeted the best biotech ETF to buy now. It offers investors an excellent way to play the entire industry, without having to pick a specific sector.

    Here’s the pick…

biotech stocks to buy

Eight New Picks from Our "Stocks to Buy Now" List (and None Are Alibaba)

stocks to buy

Best stocks to buy for the week ending Sept. 19, 2014:Last week, U.S. market history was made when Alibaba debuted as the biggest IPO of all time. While we like BABA stock, it's not the only way to profit.

You can find all of last week's recommendations here in our newest list of the best stocks to buy now.

Including 2 top biotech picks, 2 energy stocks that take advantage of recent EPA rule changes, and more...

Two of the Best Biotech Stocks to Buy Now

biotech stocks to buy

Since April 11, Gilead Sciences (Nasdaq: GILD) has scored peak gains of a 74.2% - or more than 175% annualized gains.

Some investors don't want to risk it all during a sell-off - but they still want to take advantage of the growth biotech stocks offer.

Here are two biotech stocks to buy – one appeals to risk takers and one to investors who favor a more conservative approach – and both offer plenty of upside potential…

Three of the Best Biotech Penny Stocks to Buy Now

penny stocks to buy

For investors looking for the best penny stocks to buy, the biotech sector offers some of the best investment opportunities on the market.

Despite the fact that biotech stocks have been up and down in 2014, Money Morning's Bioscience Investment Specialist Ernie Tremblay sees great profit opportunities for the rest of 2014.

Here are the three best biotech penny stocks to buy now and why they could take off…

Stocks to Buy: Intercept Pharma (Nasdaq: ICPT) Ready to Double

20140611-stocks-to-buy

Usually the best stocks to buy have not already tripled in value within the past six months.

But then there's Intercept Pharmaceuticals Inc. (Nasdaq: ICPT).

This biotech stock soared more than 500% in two days on the news its innovative and promising hepatitis drug obeticholic acid, or OCA, had a trial stopped early because the drug met the goals of the study.

Bulls have refused to be distracted by some negative news that has pushed the stock back under $300 in the meantime.

The crazy thing is, Intercept Pharma could actually double from here...

The Secret to Making Money from Bioscience's "Scariest Event"

In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs- down for an experimental drug as it makes its way through the regulatory process.

Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.

Perhaps the least  understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.

But they're also among the most powerful.

Here's what I mean, and how to play them profitably... Full Story

The Four Telltale Signs of a Bioscience "Blockbuster" in the Making

The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.

But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.

They're like big, green, neon signs that say, "This is an important drug with incredible profit potential."

And this is how you find them... Full Story

Best Stocks to Buy Now: A Hot Biopharma, an Energy Sector Worth $2 Trillion, and More

stocks to buy

Our roundup of the best stocks to buy last week gave Money Morning Members more than a dozen plays in 2014's most profitable sectors.

One pick involves a possible healthcare merger that would combine two industry titans. The duo would create an industry powerhouse with a market cap near $300 billion. Another play revolves around one of the most highly anticipated, and possibly biggest, initial public offerings ever. And a special report from our small-cap trading specialist showed readers a technique for uncovering investment winners today.

Here they are – with more opportunities – in our latest Money Morning best stocks to buy list:

Stocks to Buy: Why This Biopharma Company Is a “Long-Term Profit Machine”

20140509-stocks-to-buy-CARA

One strategy experts use when looking for the best biotech stocks to buy is finding companies with promising drug candidates that are close to receiving regulatory approval. When these drugs hit the market, they can bring in billions in revenue.

When companies have multiple promising drugs in their product pipeline, they become even more attractive because they have more than one shot at finding a revenue blockbuster.

That’s why Money Morning’s Defense & Tech Specialist Michael A. Robinson likes this biotech stock to buy now…

Stocks to Buy: This Botox Competitor Is Heading Toward Huge Profits

20140429_stocks-to-buy

When Valeant Pharmaceuticals International Inc. (NYSE: VRX) and activist investor Bill Ackman made an unsolicited $46 billion bid to purchase Botox maker Allergan Inc. (NYSE: AGN) last week, investors got a glimpse of just how big the Botox market is globally.

And that had us pointing to our "Stocks to Buy" list...

<strong><em>Money Morning</em></strong>'s Defense & Tech Specialist Michael A. Robinson has been recommending a biotech stock that develops similar specialty products for dermatological applications. And it could see huge gains soon...

Stocks to Buy: 95% Return Is Just the Start For This Biotech Play

Lab worker

Investors looking for stocks to buy in 2014 have had an abundance of new options as 94 companies have gone public this year, according to Renaissance Capital.

The average return for those 94 companies since their IPO date is 9%. But some stocks have far outpaced the average, and are still at great buy-in points even after huge gains.

Money Morning's Defense and Tech Specialist Michael Robinson has found a stock that still provides investors a great profit opportunity, even after posting a 95% return from its IPO date...

Three Orphan Drug Stocks to Buy When the Biotech Market Is Down

best biotech investments 2014

There's no sugarcoating it: Biotech stocks have had a rough run in the past month.

But when other investors are running for the hills, Money Morning experts are finding profit plays. With biotech stocks trading lower, there are excellent buy-in opportunities on valuable biotech companies.

Orphan drugs offer some of the best profit plays in biotech as the have extremely lucrative markets cornered.

And these three stocks to buy are the best orphan drug plays now...

There Is No Biotech Bubble; Here's the Real Story

20140331_IPO-bubble

Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.

But they're wrong; the market is simply in a period of adjustment.

The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.

The problem with that argument is, these analysts are using a mass of technical indicators to support it. Anyone who's followed start-up biotechs knows that's a fool's errand.

Finding the Blockbuster That Will Make You Rich

In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year.

It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on.

So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost.

There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search...

Full Story